Document is current

Article History

Accepted: 24 July 2024

First Online: 22 August 2024

Declarations

:

: This research was investigator-initiated and did not receive any funding.

: AS has served as a speaker for Sandoz and Arrowtex Pharmaceuticals, and has received advisory fees from Abbvie, Amgen, Arrotex Pharmaceuticals, Pfizer, and Takeda Pharmaceuticals. DvL has received educational grants or research support from Pfizer, Takeda, Ferring, and Shire, and has received consultancy and/or speaker’s fees from Pfizer, Janssen, AbbVie, Ferring, Vifor and Emerge Health. PDC has served as a consultant, an advisory board member, or a speaker for AbbVie, Baxter, Ferring, Janssen, Celltrion, Pfizer, Emerge Health, Shire and Takeda; is supported by an NHMRC Emerging Leader 2 Fellowship; and has received research support from AbbVie, Ferring, Shire, Janssen, Pfizer and Takeda. JS has received speaker and/or conference fees from Pfizer, Takeda Pharmaceuticals, BMS, Sandoz, Abbvie, and Celltrion, and an unrestricted grant from Tillots. AV has received advisory fees from Abbvie. RU is a paid contractor for iDose, a developer of Bayes dosing software for infliximab.

: AS conceptualised the study. AS and RU undertook modelling and data analysis. AS reviewed the literature and prepared the original manuscript. All authors critically appraised and approved the final manuscript prior to submission.

: This simulation study did not involve the use of patient data.

: Not applicable.

: Not applicable.

: The data supporting the findings of this study may be provided upon reasonable request to the corresponding author subject to approval from our Institutional Review Board.